multi class comparison
Anticoagulant Comparison: Heparin vs Warfarin vs DOACs — Onset, Monitoring, Reversal
A patient on anticoagulation starts bleeding, and the NCLEX asks what you give. Protamine, vitamin K, or idarucizumab — choosing wrong delays reversal and worsens hemorrhage. Mixing up which lab monitors which drug means you'll misinterpret results and miss a critical therapeutic failure.
Comparison
Side-by-side3 compared
Comparevs
Dimension
Heparin (UFH/LMWH)
Warfarin
DOACs
Class & mechanism
- Potentiates antithrombin → inhibits IIa & Xa
- Vitamin K antagonist → ↓ II, VII, IX, X
- Direct Xa (–xabans) or IIa (dabigatran)
Indications
- Acute VTE, ACS, periop bridging
- AFib, recurrent VTE
- ★Mechanical heart valves — DOACs not used
- AFib, VTE treatment & prevention
Route & onset
- IV (immediate) or SubQ; short half-life
- PO; onset 2–3 days, full effect 5–7 days
- PO; rapid onset, fixed dose
Key assessment
- Bleeding signs
- Platelet count for HIT
- Bleeding signs
- Dietary vitamin K, drug interactions
- Bleeding signs
- Renal function (CrCl) before dosing
Monitoring labs
- aPTT 1.5–2.5× control (UFH); anti-Xa
- ★INR 2.0–3.0 (mechanical valve 2.5–3.5)
- No routine coagulation monitoring
Adverse effects
- ★Heparin-induced thrombocytopenia (HIT)
- Bleeding; rare early skin necrosis
- Bleeding (GI most common)
Reversal / antidote
- Protamine sulfate (1 mg per 100 units)
- Vitamin K; PCC or FFP for major bleed
- Andexanet alfa (Xa); idarucizumab (dabig)
Contraindications & interactions
- Active bleeding; prior HIT
- ★Pregnancy — teratogenic (use heparin)
- Severe renal/hepatic impairment
Patient teaching
- Report unusual bleeding or bruising
- Rotate SubQ sites; do not rub or aspirate
- Report unusual bleeding or bruising
- Keep vitamin K intake consistent
- Report unusual bleeding or bruising
- Do not stop abruptly or double doses
Class & mechanism
Heparin (UFH/LMWH)
- Potentiates antithrombin → inhibits IIa & Xa
Warfarin
- Vitamin K antagonist → ↓ II, VII, IX, X
Indications
Heparin (UFH/LMWH)
- Acute VTE, ACS, periop bridging
Warfarin
- AFib, recurrent VTE
- ★Mechanical heart valves — DOACs not used
Route & onset
Heparin (UFH/LMWH)
- IV (immediate) or SubQ; short half-life
Warfarin
- PO; onset 2–3 days, full effect 5–7 days
Key assessment
Heparin (UFH/LMWH)
- Bleeding signs
- Platelet count for HIT
Warfarin
- Bleeding signs
- Dietary vitamin K, drug interactions
Monitoring labs
Heparin (UFH/LMWH)
- aPTT 1.5–2.5× control (UFH); anti-Xa
Warfarin
- ★INR 2.0–3.0 (mechanical valve 2.5–3.5)
Adverse effects
Heparin (UFH/LMWH)
- ★Heparin-induced thrombocytopenia (HIT)
Warfarin
- Bleeding; rare early skin necrosis
Reversal / antidote
Heparin (UFH/LMWH)
- Protamine sulfate (1 mg per 100 units)
Warfarin
- Vitamin K; PCC or FFP for major bleed
Contraindications & interactions
Heparin (UFH/LMWH)
- Active bleeding; prior HIT
Warfarin
- ★Pregnancy — teratogenic (use heparin)
Patient teaching
Heparin (UFH/LMWH)
- Report unusual bleeding or bruising
- Rotate SubQ sites; do not rub or aspirate
Warfarin
- Report unusual bleeding or bruising
- Keep vitamin K intake consistent
★ marks the fact that sets a column apart.
Clinical Pearl
aPTT pairs with heparin, INR pairs with warfarin, DOACs need no routine labs — match lab to drug.
⚡ Speed Sort This Table
Swipe to sort 62 clinical items into the right bucket